Sheikh, Y.; Asunramu, H.; Low, H.; Gakhar, D.; Muthukumar, K.; Yassin, H.; de Preux, L. A Cost-Utility Analysis of Mesh Prophylaxis in the Prevention of Incisional Hernias following Stoma Closure Surgery. Int. J. Environ. Res. Public Health2022, 19, 13553.
Sheikh, Y.; Asunramu, H.; Low, H.; Gakhar, D.; Muthukumar, K.; Yassin, H.; de Preux, L. A Cost-Utility Analysis of Mesh Prophylaxis in the Prevention of Incisional Hernias following Stoma Closure Surgery. Int. J. Environ. Res. Public Health 2022, 19, 13553.
Sheikh, Y.; Asunramu, H.; Low, H.; Gakhar, D.; Muthukumar, K.; Yassin, H.; de Preux, L. A Cost-Utility Analysis of Mesh Prophylaxis in the Prevention of Incisional Hernias following Stoma Closure Surgery. Int. J. Environ. Res. Public Health2022, 19, 13553.
Sheikh, Y.; Asunramu, H.; Low, H.; Gakhar, D.; Muthukumar, K.; Yassin, H.; de Preux, L. A Cost-Utility Analysis of Mesh Prophylaxis in the Prevention of Incisional Hernias following Stoma Closure Surgery. Int. J. Environ. Res. Public Health 2022, 19, 13553.
Abstract
Background: Stoma closure is a widely performed surgical procedure, with 6295 undertaken in England in 2018 alone. This procedure is associated with significant complications; incisional hernias are the most severe, occurring in 30% of patients. Complications place considerable financial burden on the NHS; hernia costs are estimated at GBP 114 million annually. As recent evidence (ROCSS, 2020) found that prophylactic meshes significantly reduce rates of incisional hernias following stoma closure surgery, an evaluation of this intervention vs. standard procedure is essential. Methods: A cost-utility analysis (CUA) was conducted using data from the ROCSS prospective multi-centre trial, which followed 790 patients, randomly assigned to mesh closure (n=394) and standard closure (n=396). Quality of life was assessed using mean EQ-5D-5L scores from the trial, and costs in GBP using UK-based sources over a 2-year time horizon. Results: The CUA yielded an incremental cost-effectiveness ratio (ICER) of GBP 128,356.25 per QALY. Additionally, two univariate sensitivity analyses were performed to test the robustness of the model. Conclusion: The results demonstrate an increased benefit with mesh prophylaxis, but at an increased cost. Although the intervention is cost-ineffective and greater than the ICER threshold of GBP 30,000/QALY (NICE), further investigation into mesh prophylaxis for at risk population groups is needed.
Medicine and Pharmacology, Gastroenterology and Hepatology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
